Peripheral glutamate levels in schizophrenia: Evidence from a meta-analysis

Neuropsychobiology

Volumn 70, Issue 3, 2014, Pages 133-141

  Song, Jiali ^a   Viggiano, Andrea ^b   Monda, Marcellino ^c   De Luca, Vincenzo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF SALERNO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Amino acids; Blood; Glutamate; Schizophrenia

Indexed keywords

GLUTAMIC ACID;

AMINO ACID BLOOD LEVEL; CASE CONTROL STUDY; EFFECT SIZE; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD; META ANALYSIS;

GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA;

EID: 84910102131     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000364828     Document Type: Review

References (39)

1. Danbolt NC: Glutamate uptake. Prog Neurobiol 2001; 65: 1-105.
2. Coyle JT: Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 363-382.
3. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G: Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol 2012; 213: 267-295.
4. Kim JS, Kornhuber HH, Holzmuller B, Schmid-Burgk W, Mergner T, Krzepinski G: Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 1980; 228: 7-10.
5. Merritt K, McGuire P, Egerton A: Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 2013; 4: 151.
6. Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR: Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 2014; 152: 325-332.
7. Hawkins RA: The blood-brain barrier and glutamate. Am J Clin Nutr 2009; 90: 867S- 874S.
8. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M: Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005; 5: 6.
9. 1 H-MRS studies. Schizophr Bull 2013; 39: 120-129.
10. Noetzel MJ, Jones CK, Conn PJ: Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Discov Med 2012; 14: 335-343.
11. Alfredsson G, Wiesel FA: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl) 1989; 99: 322-327.
12. Cai HL, Zhu RH, Li HD, Zhang XH, Hu L, Yang W, et al: Elevated plasma gamma-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1273-1278.
13. Maeshima H, Ohnuma T, Sakai Y, Shibata N, Baba H, Ihara H, et al: Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1410-1418.
14. Evins AE, Amico ET, Shih V, Goff DC: Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 1997; 104: 761-766.
15. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, et al: Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002; 51: 493-497.
16. Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, et al: Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta 2007; 380: 186-190.
17. Rao ML, Gross G, Strebel B, Braunig P, Huber G, Klosterkotter J: Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 1990; 34: 243-257.
18. Headrick TC: Statistical Simulation: Power Method Polynomials and Other Transformations. Boca Raton, Chapman & Hall/CRC, 2010.
19. Macciardi F, Lucca A, Catalano M, Marino C, Zanardi R, Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res 1990; 32: 63-70.
20. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985; 147: 276-282.
21. Ohnuma T, Sakai Y, Maeshima H, Higa M, Hanzawa R, Kitazawa M, et al: No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia. Int J Psychiatry Med 2012; 44: 17-27.
22. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982; 232: 299-304.
23. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G: A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41-51.
24. Morshed NM, Sobhan MA, Nahar JS, Keramat Ali SM, Shams M: Excitatory amino acid neurotransmitters in schizophrenia. Bangladesh Med Res Counc Bull 2005; 31: 15-20.
25. Palomino A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, Gonzalez-Garcia G, et al: Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr Res 2007; 95: 174-178.
26. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M: Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001; 44: 167-171.
27. Davis JM, Spaide JK, Himwich HE: Effects of tranylcypromine and L-cysteine on plasma amino acids in controls and schizophrenic patients. Am J Clin Nutr 1972; 25: 302-310.
28. Shulman Y, Grant S, Seres P, Hanstock C, Baker G, Tibbo P: The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci 2006; 31: 406.
29. De Luca V, Viggiano E, Messina G, Viggiano A, Borlido C, Viggiano A, et al: Peripheral amino acid levels in schizophrenia and antipsychotic treatment. Psychiatry Investig 2008; 5: 203-208.
30. Monda M, Sullo A, De Luca V, Pellicano MP, Viggiano A: L-threonine injection into PPC modifies food intake, lateral hypothalamic activity, and sympathetic discharge. Am J Physiol 1997; 273:R554-R559.
31. Bushe C, Haddad P, Peveler R, Pendlebury J: The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005; 19(suppl):28-35.
32. Kaur G, Kulkarni SK: Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 277-285.
33. Thornton-Jones Z, Neill JC, Reynolds GP: The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol 2002; 16: 35-37.
34. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, et al: Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 2008; 16: 1780-1787.
35. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F: Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150: 1731-1733.
36. van der Heijden FM, Tuinier S, Fekkes D, Sijben AE, Kahn RS, Verhoeven WM: Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004; 14: 259-265.
37. McGlashan TH: The DSM-IV version of schizophrenia may be harmful to patients' health. Early Interv Psychiatry 2007; 1: 289-293.
38. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL: Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust NZ J Psychiatry 1998; 32: 73-76.
39. He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D: Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry 2012;2:e149.